Company / Net Income
PharmaCyte Biotech, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$333.8K
FY2025
5-year range
-$4.3M / $333.8K
FY2021-FY2025
Trend
+107.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income returned to growth in FY2025 after 2 years of decline, reaching $333,763.
Based on SEC 10-K filings.
$333,763 in FY2025.
Improved from -$4M to $333,763 over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 107.7% year-over-year.
- Lowest net income in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $333.8K | +107.7% |
| FY2024 | -$4.3M | -1.8% |
| FY2023 | -$4.2M | -19.4% |
| FY2022 | -$3.6M | +7.2% |
| FY2021 | -$3.8M | +5.9% |
| FY2020 | -$4.1M | +40.4% |
| FY2019 | -$6.8M | -53.7% |
| FY2018 | -$4.4M | +26.7% |
| FY2017 | -$6.1M | +77.8% |
| FY2016 | -$27.3M | -1605.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026